[
  {
    "ts": "2025-12-21T15:44:45+00:00",
    "headline": "Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-releases-154445950.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "83db94a8-86f8-3e98-bbd6-d8c1c8417569",
      "content": {
        "id": "83db94a8-86f8-3e98-bbd6-d8c1c8417569",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for the Next 3 Years. On December 12, Eli Lilly and Company (NYSE:LLY) released updated results from Phase 3 EMBER-3 study of Inluriyo (imlunestrant), which is an oral estrogen receptor antagonist, in patients with estrogen receptor positive (ER+), human epidermal growth factor […]",
        "pubDate": "2025-12-21T15:44:45Z",
        "displayTime": "2025-12-21T15:44:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly and Company (LLY) Releases Updated Results from Phase 3 EMBER-3 Study of Inluriyo (imlunestrant)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7SniT2cAwGKi0gxMU3rg8Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OYjuUHa2wfRuGI22z0Csjw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b67cae29a642446338abc3321276426.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-releases-154445950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-releases-154445950.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]